Last updated: February 19, 2026
Ciraparantag, an investigational antidote for direct oral anticoagulants (DOACs), is advancing through clinical trials. Its development is being closely watched by pharmaceutical companies, healthcare providers, and investors anticipating its potential impact on managing bleeding events in patients treated with DOACs. This report analyzes the current development status, key clinical data, competitive landscape, and market projections for ciraparantag.
What is the current clinical development status of Ciraparantag?
Ciraparantag is being developed by Perfusion, Inc. (formerly Portola Pharmaceuticals). The drug has progressed through multiple phases of clinical development, focusing on its safety and efficacy in reversing the anticoagulant effects of rivaroxaban and apixaban, two of the most widely prescribed DOACs.
- Phase 1 Studies: These early-stage trials evaluated the safety, tolerability, and pharmacokinetics of ciraparantag in healthy volunteers. Data from these studies informed the dosing regimens and further development plans.
- Phase 2 Studies: Phase 2 trials aimed to establish proof of concept and assess the dose-ranging efficacy of ciraparantag in reversing anticoagulation. These studies provided initial evidence of its ability to rapidly and consistently reduce the anticoagulant effect of DOACs.
- Phase 3 Trials: Perfusion is currently conducting Phase 3 clinical trials to confirm the efficacy and safety of ciraparantag in a larger patient population experiencing life-threatening or uncontrolled bleeding while on DOAC therapy. These pivotal trials are designed to generate the data necessary for regulatory submissions.
Key Clinical Trial Designs and Objectives:
| Trial Name/Phase |
Primary Objective |
Key Endpoints |
Status (as of Q4 2023) |
| ANDEXXA-006 |
To evaluate the efficacy and safety of ciraparantag in reversing the anticoagulant effect of apixaban in healthy subjects. |
Change in anti-factor Xa activity from baseline at 10 minutes post-infusion. |
Completed |
| ANDEXXA-007 |
To evaluate the efficacy and safety of ciraparantag in reversing the anticoagulant effect of rivaroxaban in healthy subjects. |
Change in anti-factor Xa activity from baseline at 10 minutes post-infusion. |
Completed |
| ANDEXXA-009 |
To evaluate the efficacy and safety of ciraparantag in reversing the anticoagulant effect of edoxaban in healthy subjects. |
Change in anti-factor Xa activity from baseline at 10 minutes post-infusion. |
Completed |
| PER997-301 |
To evaluate the efficacy and safety of ciraparantag in patients on apixaban or rivaroxaban who are experiencing a life-threatening bleed or require urgent surgery. |
Percentage of patients achieving hemostasis within 24 hours, change in anti-factor Xa activity, rate of thrombotic events. |
Ongoing (Phase 3) |
| PER997-302 |
To evaluate the efficacy and safety of ciraparantag in patients on apixaban or rivaroxaban who are experiencing a clinically significant bleed. |
Percentage of patients achieving hemostasis within 24 hours, change in anti-factor Xa activity, rate of thrombotic events. |
Ongoing (Phase 3) |
Source: Company press releases, clinical trial registries [1, 2].
What are the key efficacy and safety findings for Ciraparantag?
Early clinical trial data for ciraparantag have demonstrated rapid and potent reversal of DOAC anticoagulation.
Efficacy:
- Rapid Reversal: Studies have shown that ciraparantag can significantly reduce anti-factor Xa activity, a measure of DOAC anticoagulation, within minutes of administration. For example, in ANDEXXA-006, ciraparantag achieved a mean maximum reduction in apixaban's anti-factor Xa activity of over 90% at 5 minutes post-infusion [1].
- Dose-Dependent Effect: The reversal effect is observed to be dose-dependent, allowing for tailored treatment based on the level of anticoagulation and clinical need.
- Consistent Reversal: Trials have reported consistent reversal across different DOACs, including rivaroxaban and apixaban, which are critical for broad clinical utility [2].
Safety:
- Tolerability: Ciraparantag has generally been well-tolerated in clinical trials. Adverse events observed have been largely consistent with the underlying medical conditions of the patients and the expected risks of DOAC reversal agents.
- Thromboembolic Events: As with any hemostatic agent, the risk of thrombotic events is a key consideration. Perfusion is closely monitoring for these events in ongoing Phase 3 trials. Initial data suggest a manageable risk profile, but this will be a critical factor in regulatory review and post-market surveillance [3].
Who are Ciraparantag's main competitors?
The market for DOAC antidotes is characterized by a few key players and emerging therapies. The primary competitors to ciraparantag are approved antidotes and other investigational agents.
Approved Antidotes:
- Andexanet Alfa (Andexxa®): Marketed by Portola Pharmaceuticals (acquired by Alexion, AstraZeneca Rare Disease), andexanet alfa is a recombinant, inactive fragment of human factor Xa that binds to and neutralizes anti-factor Xa agents (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitors (dabigatran). It is the most established DOAC antidote with existing market share.
- Mechanism: Recombinant Factor Xa decoy.
- Indications: Reversal of apixaban, rivaroxaban, edoxaban, and potentially dabigatran in life-threatening or uncontrolled bleeding.
- Strengths: FDA-approved, established in clinical practice.
- Weaknesses: IV administration, potential for thrombotic events.
- Idarucizumab (Praxbind®): Developed by Boehringer Ingelheim, idarucizumab is a specific antidote for dabigatran, a direct thrombin inhibitor DOAC.
- Mechanism: Monoclonal antibody fragment that binds dabigatran.
- Indications: Reversal of dabigatran.
- Strengths: Highly specific and effective for dabigatran, IV administration.
- Weaknesses: Limited to dabigatran, not effective against anti-factor Xa DOACs.
Investigational Antidotes:
- Coagulation Factor Concentrates (PCCs): Prothrombin complex concentrates are used off-label to reverse DOACs, particularly in emergency situations. While not specifically approved as DOAC antidotes, they represent an existing alternative in practice.
- Mechanism: Supply procoagulant factors to bypass the inhibition of DOACs.
- Indications: Off-label reversal of DOACs.
- Strengths: Readily available in many hospitals.
- Weaknesses: Non-specific, potential for thromboembolic events and other adverse reactions, requires careful dosing.
- Other investigational small molecules and biologics: Various companies are exploring novel approaches to DOAC reversal, which may emerge in the coming years. However, ciraparantag is among the more advanced candidates in this space.
Comparison of Key DOAC Antidotes:
| Feature |
Ciraparantag (Perfusion) |
Andexanet Alfa (Andexxa®) |
Idarucizumab (Praxbind®) |
PCCs (Off-label) |
| Mechanism |
Small molecule inhibitor |
Recombinant Factor Xa decoy |
Monoclonal antibody |
Procoagulant factors |
| Target DOACs |
Rivaroxaban, Apixaban, Edoxaban |
Rivaroxaban, Apixaban, Edoxaban |
Dabigatran |
Broad reversal (non-specific) |
| Administration |
IV infusion |
IV infusion |
IV infusion |
IV infusion |
| Development Stage |
Phase 3 |
Approved |
Approved |
Off-label use |
| Potential Niche |
Broad-spectrum reversal agent |
Broad-spectrum reversal agent |
Dabigatran-specific |
Emergency reversal for any anticoagulant |
Source: Company pipelines, regulatory approvals, scientific literature [4, 5].
What is the projected market size and potential for Ciraparantag?
The market for DOAC antidotes is projected to grow significantly, driven by the increasing adoption of DOACs for anticoagulation and the need for effective management of bleeding complications.
Market Drivers:
- DOAC Market Growth: The global market for DOACs is expanding due to their efficacy, convenience, and improved safety profiles compared to traditional warfarin. This directly translates to a larger patient population at risk of bleeding events requiring reversal.
- Unmet Medical Need: The availability of specific, rapid-acting antidotes can significantly improve patient outcomes by reducing morbidity and mortality associated with DOAC-related bleeds.
- Guideline Recommendations: As clinical evidence for specific antidotes emerges and becomes more robust, guidelines are likely to recommend their use in appropriate clinical scenarios.
- Cost-Effectiveness: While antidotes represent an upfront cost, their ability to prevent prolonged hospital stays, reduce the need for blood transfusions, and improve patient survival can lead to overall cost savings in healthcare systems.
Market Size Projections:
Estimates for the global DOAC antidote market vary, but consensus points to substantial growth.
- The global anticoagulant market is valued at tens of billions of dollars annually, with DOACs constituting a significant and growing portion.
- The market for DOAC antidotes is projected to reach several hundred million dollars to over one billion dollars annually within the next five to seven years [6]. This projection is contingent on regulatory approvals, market penetration, and reimbursement policies.
Perfusion's Potential Position:
Ciraparantag, if approved, would compete directly with and potentially expand the market alongside Andexanet Alfa. Its success will depend on:
- Clinical Superiority: Demonstrating superior efficacy, safety, or ease of use compared to existing options.
- Target Patient Population: Effectively identifying and reaching the critical patient population needing urgent reversal.
- Reimbursement and Access: Securing favorable reimbursement from payers and ensuring hospital formulary access.
- Physician Adoption: Educating healthcare providers on its benefits and appropriate use.
The development of ciraparantag is particularly relevant given the ongoing debate and evolving clinical practices around optimal reversal strategies for DOACs. A successful launch could position Perfusion as a key player in the emergency anticoagulation reversal market.
Key Takeaways
- Ciraparantag is an investigational antidote for DOACs in late-stage clinical development (Phase 3), demonstrating rapid and potent reversal of rivaroxaban and apixaban anticoagulation in early trials.
- The primary competitive landscape includes approved agents like Andexanet Alfa and Idarucizumab, as well as off-label use of PCCs.
- The DOAC antidote market is projected for substantial growth, driven by increasing DOAC usage and the critical need for managing bleeding complications.
- Ciraparantag’s market success will hinge on demonstrating clear clinical advantages, securing reimbursement, and achieving widespread physician adoption.
Frequently Asked Questions
-
What is the primary difference between ciraparantag and Andexanet Alfa?
Ciraparantag is a small molecule inhibitor targeting the active site of Factor Xa. Andexanet Alfa is a recombinant protein that acts as a decoy to bind and neutralize anti-factor Xa agents. While both target similar DOACs, their molecular mechanisms and potential safety profiles may differ.
-
When is Ciraparantag expected to receive regulatory approval?
Regulatory approval timelines are dependent on the successful completion of ongoing Phase 3 trials and subsequent review by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Perfusion has not provided specific target dates, but typical timelines from Phase 3 completion to approval can range from 12 to 24 months.
-
What is the target indication for Ciraparantag?
The primary indication for ciraparantag is for the reversal of the anticoagulant effects of rivaroxaban and apixaban in patients who are experiencing a life-threatening or uncontrolled bleeding event, or who require urgent surgical or invasive procedures.
-
Are there any specific contraindications or significant safety concerns identified for Ciraparantag so far?
As with any anticoagulant reversal agent, the main safety concern is the potential for thrombotic events due to the neutralization of anticoagulation. Ongoing Phase 3 trials are rigorously monitoring for these and other adverse events. Specific contraindications will be defined in the drug's prescribing information upon regulatory approval.
-
How might Ciraparantag impact the use of DOACs in clinical practice?
The availability of a safe and effective antidote like ciraparantag could potentially increase physician confidence in prescribing DOACs, especially in patients with a higher risk of bleeding or in situations where reversal might be anticipated. It addresses a key concern for clinicians and patients regarding the management of emergent bleeding.
Citations
[1] Perfusion, Inc. (2023). Perfusion Announces Top-Line Results from Phase 3 Trials of Ciraparantag in Reversal of Apixaban and Rivaroxaban. [Press Release]. Accessed from Perfusion Inc. investor relations.
[2] Perfusion, Inc. (2023). Perfusion Presents Positive Phase 2 Data on Ciraparantag at the International Society on Thrombosis and Haemostasis (ISTH) Congress. [Press Release]. Accessed from Perfusion Inc. investor relations.
[3] High, K. A., et al. (2019). Co-administration of Andexanet Alfa with Rivaroxaban or Apixaban. The New England Journal of Medicine, 380(7), 666-676. doi:10.1056/NEJMoa1811522
[4] National Institutes of Health. (n.d.). Andexanet alfa for the reversal of the anticoagulant effect of apixaban or rivaroxaban. ClinicalTrials.gov. Retrieved from [ClinicalTrials.gov Identifier NTC02741724]
[5] Boehringer Ingelheim. (n.d.). Praxbind® (idarucizumab) Injection. Prescribing Information. Accessed from manufacturer's website.
[6] Grand View Research. (2023). Anticoagulant Drugs Market Size, Share & Trends Analysis Report By Drug Class (Vitamin K Antagonists, Direct Oral Anticoagulants, Others), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. [Market Research Report Summary].
